Lupus, the current therapeutic approaches

Drugs of Today

Volumn 47, Issue 4, 2011, Pages 289-302

  Wong, Maida ^a   La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CD20 ANTIBODY; CD20 ANTIGEN; CELL SURFACE PROTEIN; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC AGENT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OCRELIZUMAB; OLIGONUCLEOTIDE; PLACEBO; PREDNISONE; RITUXIMAB; SYNTHETIC PEPTIDE; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

ATHEROSCLEROSIS; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CELL SURVIVAL; CELL THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MUCOSA INFLAMMATION; NEUROPATHY; NONHUMAN; PANCYTOPENIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINOPATHY; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; STEM CELL TRANSPLANTATION; TISSUE THERAPY;

EID: 80052755594     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.4.1583186     Document Type: Review

References (158)

1. Karim, M.Y., Pisoni, C.N., Khamashta, M.A. Update on immunotherapy for systemic lupus erythematosus-what's hot and what's not! Rheumatology (Oxford) 2009, 48(4): 332-41.
2. Looney, R.J., Anolik, J., Sanz, I. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2010, 20(1): 1-10.
3. Iikuni, N., La Cava, A. Antibody-based therapies in systemic lupus erythematosus. Mini Rev Med Chem 2009, 9(7): 829-46.
4. Iikuni, N., Hahn, B.H., La Cava, A. Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus. Expert Opin Biol Ther 2009, 9(2): 201-6.
5. Datta, S.K. Major peptide autoepitopes for nucleosome-centered T and B cell interaction in human and murine lupus. Ann N Y Acad Sci 2003, 987: 79-90.
6. Dong, L., Ito, S., Ishii, K.J., Klinman, D.M. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum 2005, 52(2): 651-8.
7. Klinman, D.M., Tross, D., Klaschik, S., Shirota, H., Sato, T. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Ann N Y Acad Sci 2009, 1175: 80-8.
8. Ferrera, F., Filaci, G., Rizzi, M., Singh, R.P., Indiveri, F., Hahn, B.H., La Cava, A. New therapies in SLE. Recent Pat Inflamm Allergy Drug Discov 2008, 2(1): 11-23.
9. Boumpas, D.T., Austin, H.A., 3rd, Vaughn, E.M., Klippel, J.H., Steinberg, A.D., Yarboro, C.H., Balow, J.E. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 340(8822): 741-5.
10. Esdaile, J.M. How to manage patients with lupus nephritis. Best Pract Res Clin Rheumatol 2002, 16(2): 195-210.
11. Flanc, R.S., Roberts, M.A., Strippoli, G.F., Chadban, S.J., Kerr, P.G., Atkins, R.C. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004, 43(2): 197-208.
12. Grootscholten, C., Ligtenberg, G., Hagen, E.C. et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006, 70(4): 732-42.
13. Steinberg, A.D., Steinberg, S.C. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991, 34(8): 945-50.
14. Houssiau, F.A., Vasconcelos, C., D'Cruz, D. et al. Immunosuppressive therapy in lupus nephritis: the Euro- Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46(8): 2121-31.
15. D'Cruz, D., Cuadrado, M.J., Mujic, F. et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997, 15(3): 275-82.
16. Somers, E.C., Marder, W., Christman, G.M., Ognenovski, V., McCune, W.J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005, 52(9): 2761-7.
17. Chan, T.M., Li, F.K., Tang, C.S. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343(16): 1156-62.
18. Morris, R.E., Hoyt, E.G., Murphy, M.P., Eugui, E.M., Allison, A.C. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990, 22(4): 1659-62.
19. Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., Roth, D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350(10): 971-80.
20. Vasoo, S. First international meeting on mycophenolate mofetil: an advance in the treatment of lupus. 27 April 2004, St Thomas' Hospital, London, UK. Lupus 2004, 13(7): 543-5.
21. Appel, G.B., Contreras, G., Dooley, M.A. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20(5): 1103-12.
22. Radhakrishnan, J., Moutzouris, D.A., Ginzler, E.M., Solomons, N., Siempos, II, Appel, G.B. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010, 77(2): 152-60.
23. Isenberg, D., Appel, G.B., Contreras, G. et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010, 49(1): 128-40.
24. Mak, A., Cheak, A.A., Tan, J.Y., Su, H.C., Ho, R.C., Lau, C.S. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009, 48(8): 944-52.
25. Tanaka, H., Oki, E., Tsuruga, K., Yashiro, T., Hanada, I., Ito, E. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol 2009, 72(6): 430-6.
26. Asamiya, Y., Uchida, K., Otsubo, S., Takei, T., Nitta, K. Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clin Pract 2009, 113(4): c330-6.
27. Miyasaka, N., Kawai, S., Hashimoto, H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled doubleblind multicenter study. Mod Rheumatol 2009, 19(6): 606-15.
28. Ogawa, H., Kameda, H., Amano, K., Takeuchi, T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 2010, 19(2): 162-9.
29. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., Khamashta, M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69(1): 20-8.
30. Tsakonas, E., Joseph, L., Esdaile, J.M. et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998, 7(2): 80-5.
31. Ruiz-Irastorza, G., Khamashta, M.A., Hughes, G.R. Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 2000, 9(7): 1581-93.
32. Sato, E.I. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001, 10(3): 162-4.
33. Abu-Shakra, M., Shoenfeld, Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001, 10(3): 152-3.
34. Dimopoulos, M.A., Anagnostopoulos, A., Weber, D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003, 21(23): 4444-54.
35. Jessop, S., Whitelaw, D.A., Delamere, F.M. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009(4): CD002954.
36. Cuadrado, M.J., Karim, Y., Sanna, G., Smith, E., Khamashta, M.A., Hughes, G.R. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005, 118(3): 246-50.
37. Tam, L.S., Li, E.K., Wong, C.K., Lam, C.W., Li, W.C., Szeto, C.C. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 2006, 65(3): 417-8.
38. Grammer, A.C., Lipsky, P.E. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003, 5(Suppl. 4): S22-7.
39. Chan, O.T., Madaio, M.P., Shlomchik, M.J. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999, 169: 107-21.
40. Riley, J.K., Sliwkowski, M.X. CD20: a gene in search of a function. Semin Oncol 2000, 27(6, Suppl. 12): 17-24.
41. Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6(4): 443-6.
42. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., Tedder, T.F. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199(12): 1659-69.
43. Hamaguchi, Y., Uchida, J., Cain, D.W., Venturi, G.M., Poe, J.C., Haas, K.M., Tedder, T.F. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005, 174(7): 4389-99.
44. Gong, Q., Ou, Q., Ye, S. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005, 174(2): 817-26.
45. Vigna-Perez, M., Hernandez-Castro, B., Paredes- Saharopulos, O., Portales-Perez, D., Baranda, L., Abud- Mendoza, C., Gonzalez-Amaro, R. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8(3): R83.
46. Leandro, M.J., Cambridge, G., Edwards, J.C., Ehrenstein, M.R., Isenberg, D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44(12): 1542-5.
47. Taylor, R.P., Lindorfer, M.A. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007, 3(2): 86-95.
48. Maloney, D.G., Smith, B., Rose, A. Rituximab: mechanism of action and resistance. Semin Oncol 2002, 29(1, Suppl. 2): 2-9.
49. Ng, K.P., Cambridge, G., Leandro, M.J., Edwards, J.C., Ehrenstein, M., Isenberg, D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007, 66(9): 1259-62.
50. Anolik, J.H., Barnard, J., Cappione, A., Pugh-Bernard, A.E., Felgar, R.E., Looney, R.J., Sanz, I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50(11): 3580-90.
51. Leandro, M.J., Edwards, J.C., Cambridge, G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002, 61(10): 883-8.
52. Molloy, E.S., Calabrese, L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008, 8(2): 144-6.
53. Merrill, J.T., Neuwelt, C.M., Wallace, D.J. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62(1): 222-33.
54. Favas, C., Isenberg, D.A. B-cell-depletion therapy in SLE - what are the current prospects for its acceptance? Nat Rev Rheumatol 2009, 5(12): 711-6.
55. Albert, D., Dunham, J., Khan, S. et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008, 67(12): 1724-31.
56. A study to evaluate two doses of ocrelizumab in patients with active systemic lupus erythematosus (BEGIN) (NCT00539838). ClinicalTrials.gov Web site, Accessed April 27, 2011.
57. A study to evaluate oreclizumab in patients with nephritis due to systemic lupus erythematosus (BELONG) (NCT00626197). ClinicalTrials.gov Web site, Accessed April 27, 2011.
58. Tedder, T.F., Tuscano, J., Sato, S., Kehrl, J.H. CD22, a B lymphocyte- specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997, 15: 481-504.
59. Crocker, P.R., Paulson, J.C., Varki, A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007, 7(4): 255-66.
60. Jacobi, A.M., Goldenberg, D.M., Hiepe, F., Radbruch, A., Burmester, G.R., Dorner, T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008, 67(4): 450-7.
61. Dorner, T., Kaufmann, J., Wegener, W.A., Teoh, N., Goldenberg, D.M., Burmester, G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006, 8(3): R74.
62. Sutherland, A.P., Mackay, F., Mackay, C.R. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 2006, 112(3): 774-86.
63. Ramanujam, M., Davidson, A. The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther 2004, 6(5): 197-202.
64. Stohl, W., Metyas, S., Tan, S.M. et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48(12): 3475-86.
65. Zhang, J., Roschke, V., Baker, K.P. et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166(1): 6-10.
66. Cheema, G.S., Roschke, V., Hilbert, D.M., Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44(6): 1313-9.
67. Schiffer, L., Bethunaickan, R., Ramanujam, M. et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008, 180(3): 1938-47.
68. Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta; BmAb; LymphoStat-B. Drugs R D 2010, 10(1): 55-65.
69. A study of belimumab, a fully human monoclonal anti-BLyS antibody, in subjects with systemic lupus erythematosus (SLE) (NCT00424476). ClinicalTrials.gov Web site, Accessed April 27, 2011.
70. A study of belimumab, a fully human monoclonal anti-BLyS antibody, in subjects with systemic lupus erythematosus (SLE) (NCT00410384). ClinicalTrials.gov Web site, Accessed April 27, 2011.
71. Lateef, A., Petri, M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010, 22(5): 504-9.
72. Ramanujam, M., Wang, X., Huang, W. et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006, 116(3): 724-34.
73. The efficacy and safety of atacicept in combination with mycophenolate mofetil used to treat lupus nephritis (NCT00573157). ClinicalTrials.gov Web site, Accessed April 27, 2011.
74. Pasare, C., Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299(5609): 1033-6.
75. Linker-Israeli, M., Deans, R.J., Wallace, D.J., Prehn, J., Ozeri-Chen, T., Klinenberg, J.R. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991, 147(1): 117-23.
76. Tackey, E., Lipsky, P.E., Illei, G.G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004, 13(5): 339-43.
77. Illei, G.G., Shirota, Y., Yarboro, C.H. et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an openlabel phase I dosage-escalation study. Arthritis Rheum 2010, 62(2): 542-52.
78. Ishida, H., Muchamuel, T., Sakaguchi, S., Andrade, S., Menon, S., Howard, M. Continuous administration of antiinterleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179(1): 305-10.
79. Yin, Z., Bahtiyar, G., Zhang, N. et al. IL-10 regulates murine lupus. J Immunol 2002, 169(4): 2148-55.
80. Llorente, L., Richaud-Patin, Y., Garcia-Padilla, C. et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000, 43(8): 1790-800.
81. Feng, X., Wu, H., Grossman, J.M. et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54(9): 2951-62.
82. Baechler, E.C., Batliwalla, F.M., Karypis, G. et al. Interferoninducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100(5): 2610-5.
83. Bengtsson, A.A., Sturfelt, G., Truedsson, L., Blomberg, J., Alm, G., Vallin, H., Ronnblom, L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000, 9(9): 664-71.
84. A study to evaluate safety and tolerability of IV or SC dose of MEDI-545 in patients with systemic lupus erythematosus (NCT01031836). ClinicalTrials.gov Web site, Accessed April 27, 2011.
85. A study to evaluate the safety and tolerability of multiple IV doses of an antibody, in patients with systemic lupus erythematosus (NCT00482989). ClinicalTrials.gov Web site, Accessed April 27, 2011.
86. Safety and tolerability of MEDI-545 in patients who have mild systemic lupus erythematosus (SLE) with cutaneous involvement (NCT00299819). ClinicalTrials.gov Web site, Accessed April 27, 2011.
87. A study to evaluate safety and tolerability of subcutaneous doses of MEDI-545 in subjects with lupus (NCT00657189). ClinicalTrials.gov Web site, Accessed April 27, 2011.
88. Hill, C.M., Lunec, J. The TNF-ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Mol Aspects Med 1996, 17(5): 455-509.
89. Swale, V.J., Perrett, C.M., Denton, C.P., Black, C.M., Rustin, M.H. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003, 28(6): 604-7.
90. Tracey, D., Klareskog, L., Sasso, E.H., Salfeld, J.G., Tak, P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117(2): 244-79.
91. Aringer, M., Graninger, W.B., Steiner, G., Smolen, J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004, 50(10): 3161-9.
92. Etanercept for the treatment of lupus nephritis (NCT00447265). ClinicalTrials.gov Web site, Accessed April 27, 2011.
93. Lohr, J., Knoechel, B., Jiang, S., Sharpe, A.H., Abbas, A.K. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003, 4(7): 664-9.
94. Daikh, D.I., Finck, B.K., Linsley, P.S., Hollenbaugh, D., Wofsy, D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997, 159(7): 3104-8.
95. Wang, X., Huang, W., Mihara, M., Sinha, J., Davidson, A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002, 168(4): 2046-53.
96. Schiffer, L., Sinha, J., Wang, X. et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003, 171(1): 489-97.
97. Merrill, J.T., Burgos-Vargas, R., Westhovens, R., et al. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. 72nd Annu Sci Meet Am Coll Rheumatol (Oct 24-29, San Francisco) 2008, Abst L15.
98. Efficacy and safety study of abatacept to treat lupus nephritis (NCT00430677). ClinicalTrials.gov Web site, Accessed April 27, 2011.
99. Abatacept and cyclophosphamide combination therapy for lupus nephritis (ACCESS) (NCT00774852). ClinicalTrials.gov Web site, Accessed April 27, 2011.
100. Salomon, B., Bluestone, J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19: 225-52.
101. Wang, X., Huang, W., Schiffer, L.E., Mihara, M., Akkerman, A., Hiromatsu, K., Davidson, A. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003, 48(2): 495-506.
102. Sidiropoulos, P.I., Boumpas, D.T. Lessons learned from anti- CD40L treatment in systemic lupus erythematosus patients. Lupus 2004, 13(5): 391-7.
103. Kalunian, K.C., Davis, J.C., Jr., Merrill, J.T., Totoritis, M.C., Wofsy, D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46(12): 3251-8.
104. Boumpas, D.T., Furie, R., Manzi, S., Illei, G.G., Wallace, D.J., Balow, J.E., Vaishnaw, A. A short course of BG9588 (anti- CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48(3): 719-27.
105. Huang, W., Sinha, J., Newman, J. et al. The effect of anti- CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002, 46(6): 1554-62.
106. Hutloff, A., Dittrich, A.M., Beier, K.C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., Kroczek, R.A. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397(6716): 263-6.
107. Lohning, M., Hutloff, A., Kallinich, T. et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 2003, 197(2): 181-93.
108. Iwai, H., Abe, M., Hirose, S. et al. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 2003, 171(6): 2848-54.
109. A study of AMG 557 in adults with systemic lupus erythematosus (NCT00774943). ClinicalTrials.gov Web site, Accessed April 27, 2011.
110. Sun, Y., Blink, S.E., Chen, J.H., Fu, Y.X. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling. J Immunol 2005, 175(2): 884-90.
111. Foell, J., Strahotin, S., O'Neil, S.P. et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003, 111(10): 1505-18.
112. Sun, Y., Chen, H.M., Subudhi, S.K., Chen, J., Koka, R., Chen, L., Fu, Y.X. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002, 8(12): 1405-13.
113. Kim, J., Choi, W.S., La, S. et al. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood 2005, 105(5): 2206-13.
114. La Cava, A., Fang, C.J., Singh, R.P., Ebling, F., Hahn, B.H. Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev 2005, 4(8): 515-9.
115. Mohan, C., Adams, S., Stanik, V., Datta, S.K. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993, 177(5): 1367-81.
116. Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389(6648): 251-60.
117. Wu, H.Y., Staines, N.A. A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 2004, 13(3): 192-200.
118. Kaliyaperumal, A., Michaels, M.A., Datta, S.K. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 1999, 162(10): 5775-83.
119. Riemekasten, G., Marell, J., Trebeljahr, G. et al. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest 1998, 102(4): 754-63.
120. Dieker, J.W., Van Bavel, C.C., Riemekasten, G., Berden, J.H., van der Vlag, J. The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes. Ann Rheum Dis 2006, 65(11): 1525-8.
121. Riemekasten, G., Weiss, C., Schneider, S. et al. T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus. Ann Rheum Dis 2002, 61(9): 779-85.
122. Riemekasten, G., Langnickel, D., Enghard, P. et al. Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 2004, 173(9): 5835-42.
123. Monneaux, F., Lozano, J.M., Patarroyo, M.E., Briand, J.P., Muller, S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol 2003, 33(2): 287-96.
124. Monneaux, F., Hoebeke, J., Sordet, C. et al. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog. J Immunol 2005, 175(9): 5839-47.
125. Hahn, B.H., Singh, R.R., Wong, W.K., Tsao, B.P., Bulpitt, K., Ebling, F.M. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001, 44(2): 432-41.
126. La Cava, A., Ebling, F.M., Hahn, B.H. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 2004, 173(5): 3542-8.
127. Hahn, B.H., Singh, R.P., La Cava, A., Ebling, F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol 2005, 175(11): 7728-37.
128. Singh, R.P., La Cava, A., Wong, M., Ebling, F., Hahn, B.H. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 2007, 178(12): 7649-57.
129. Singh, R.P., La Cava, A., Hahn, B.H. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 2008, 180(4): 2069-80.
130. Lourenco, E.V., Procaccini, C., Ferrera, F. et al. Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice. J Immunol 2009, 182(12): 7415-21.
131. Hahn, B.H., Anderson, M., Le, E., La Cava, A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58(8): 2488-97.
132. La Cava, A. Immunotherapy with peptides in systemic lupus erythematosus. Curr Med Chem 2009, 16(12): 1482-8.
133. Sthoeger, Z.M., Dayan, M., Tcherniack, A. et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 2003, 131(2): 385-92.
134. Waisman, A., Shoenfeld, Y., Blank, M., Ruiz, P.J., Mozes, E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 1995, 7(4): 689-96.
135. Luger, D., Dayan, M., Zinger, H., Liu, J.P., Mozes, E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004, 24(6): 579-90.
136. Lapter, S., Marom, A., Meshorer, A. et al. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis Rheum 2009, 60(12): 3744-54.
137. Zinger, H., Eilat, E., Meshorer, A., Mozes, E. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F1 mice via active suppression. Int Immunol 2003, 15(2): 205-14.
138. Sharabi, A., Zinger, H., Zborowsky, M., Sthoeger, Z.M., Mozes, E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by upregulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci U S A 2006, 103(23): 8810-5.
139. Sharabi, A., Mozes, E. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3- expressing CD4 cells. J Immunol 2008, 181(5): 3243-51.
140. Sharabi, A., Luger, D., Ben-David, H., Dayan, M., Zinger, H., Mozes, E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 2007, 179(8): 4979-87.
141. Rapoport, M.J., Sharabi, A., Aharoni, D., Bloch, O., Zinger, H., Dayan, M., Mozes, E. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 2005, 117(3): 262-70.
142. Sela, U., Mauermann, N., Hershkoviz, R. et al. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function. J Immunol 2005, 175(11): 7255-63.
143. Sthoeger, Z.M., Sharabi, A., Molad, Y., Asher, I., Zinger, H., Dayan, M., Mozes, E. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 2009, 33(1): 77-82.
144. Bickerstaff, M.C., Botto, M., Hutchinson, W.L. et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999, 5(6): 694-7.
145. Kanzler, H., Barrat, F.J., Hessel, E.M., Coffman, R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13(5): 552-9.
146. Lenert, P.S. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006, 8(1): 203.
147. Lau, C.M., Broughton, C., Tabor, A.S. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005, 202(9): 1171-7.
148. Wagner, H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006, 91: 159-73.
149. Klinman, D., Shirota, H., Tross, D., Sato, T., Klaschik, S. Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol 2008, 84(4): 958-64.
150. Zorro, S., Arias, M., Riano, F. et al. Response to ODN-CpG by B cells from patients with systemic lupus erythematosus correlates with disease activity. Lupus 2009, 18(8): 718-26.
151. Lenert, P., Yasuda, K., Busconi, L. et al. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRLFas(lpr/lpr) mice in vivo. Arthritis Res Ther 2009, 11(3): R79.
152. Gursel, I., Gursel, M., Yamada, H., Ishii, K.J., Takeshita, F., Klinman, D.M. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003, 171(3): 1393-400.
153. Cardiel, M.H., Tumlin, J.A., Furie, R.A., Wallace, D.J., Joh, T., Linnik, M.D. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008, 58(8): 2470-80.
154. Furie, R.A., Cash, J.M., Cronin, M.E. et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001, 28(2): 257-65.
155. Alarcon-Segovia, D., Tumlin, J.A., Furie, R.A. et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, doubleblind, placebo-controlled study. Arthritis Rheum 2003, 48(2): 442-54.
156. van Laar, J.M., Tyndall, A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006, 45(10): 1187-93.
157. Burt, R.K., Traynor, A., Statkute, L. et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006, 295(5): 527-35.
158. Sun, L., Wang, D., Liang, J. et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010, 62(8): 2467-75.